New combo therapy aims to make inoperable stomach cancer removable
NCT ID NCT07304258
First seen Jan 07, 2026 · Last updated May 08, 2026 · Updated 20 times
Summary
This study tests a combination of heated chemotherapy delivered directly to the abdomen (HIPEC), standard chemotherapy (NIPS), and an immunotherapy drug (tislelizumab) in 30 people with stomach cancer that has spread to the lining of the abdomen. The goal is to shrink the cancer enough so that it can be completely removed by surgery. Participants must not have had prior cancer treatment and must have a specific type of cancer (HER2-negative, PD-L1 positive).
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER PERITONEAL METASTASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fourth Affiliated Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.